Every material Form 8-K Alkermes filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alkermes amended its agreement to acquire Avadel Pharmaceuticals, raising the cash payment from $18.50 to $21.00 per Avadel share, with the $1.50 contingent value right unchanged. To fund the cash payment, Alkermes entered an amended bridge term loan of up to $1.5 billion that carries variable-rate interest and covenants, and Avadel's board said Lundbeck's competing proposal no longer qualifies as superior. Shareholders face a higher acquisition price and more debt, with closing still expected in the first quarter of 2026.
Cash consideration raised from $18.50 to $21.00 per Avadel share; CVR of up to $1.50 per share unchanged
Total consideration up to $22.50 per share, valuing Avadel at up to approximately $2.37 billion if the milestone payment is made
Bridge loan of up to $1.5 billion with JPMorgan Chase, maturing 364 days after funding; interest at Term SOFR plus 3.00% or base rate plus 2.00%
Avadel board determined Lundbeck's proposal no longer a Company Superior Proposal; closing expected in the first quarter of 2026
Alkermes reported third-quarter 2025 total revenues of $394.2 million, up from $378.1 million a year earlier, while GAAP net income fell to $82.8 million, or $0.49 per diluted share, from $92.4 million, or $0.55 per diluted share, in the prior-year quarter. The company raised its 2025 expectations, including total revenues of $1,430 million to $1,490 million and GAAP net income of $230 million to $250 million, and the filing notes the proposed acquisition of Avadel Pharmaceuticals announced the prior week.
Q3 2025 total revenues were $394.2 million vs. $378.1 million in Q3 2024; LYBALVI revenues were $98.2 million, up 32%.
GAAP net income was $82.8 million ($0.49 diluted EPS) vs. $92.4 million ($0.55 diluted EPS) in Q3 2024.
2025 total revenue guidance raised to $1,430 million to $1,490 million from $1,340 million to $1,430 million; GAAP net income guidance raised to $230 million to $250 million from $175 million to $205 million.
Cash, cash equivalents and total investments were $1.14 billion at Sept. 30, 2025, vs. $1.05 billion at June 30, 2025.
Alkermes agreed to acquire Avadel Pharmaceuticals through a court-sanctioned Irish scheme of arrangement, with Avadel becoming a wholly owned subsidiary. Avadel shareholders would receive $18.50 per share in cash plus a contingent value right worth up to an additional $1.50 per share, for total consideration of up to $20.00 per share. The deal is expected to close in the first quarter of 2026, subject to Avadel shareholder approval, a High Court sanction and US antitrust clearance, and Alkermes expects it to be immediately accretive.
Cash consideration of $18.50 per Avadel share, plus a CVR of up to $1.50 per share tied to FDA approval of LUMRYZ for idiopathic hypersomnia in adults by the end of 2028
Equity value of approximately $2.1 billion, a 12% premium to Avadel's October 21, 2025 closing price and a 38% premium to its three-month weighted average price
Alkermes expects to fund the deal with cash on hand and new debt; J.P. Morgan has provided fully committed financing
Expected close in the first quarter of 2026; termination fee payable by Avadel is capped at 1% of total cash consideration
On September 9, 2025, Alkermes subsidiary APIL signed an authorized generic supply agreement with Amneal Pharmaceuticals for a generic version of VIVITROL in the United States. The same filing reports patent infringement lawsuits over LYBALVI filed in August and early September 2025 against Teva, Apotex and MSN, which trigger FDA approval stays under the Hatch-Waxman Act.
Amneal may distribute the authorized generic VIVITROL for a one-year term starting on a third-party ANDA product launch, with rights ending if no launch occurs within 90 days after January 15, 2027, unless an earlier date applies.
APIL supply volume to Amneal is capped at approximately 15% of 2024 VIVITROL unit sales, with supply priced at a premium to APIL's fully burdened manufacturing cost and net profits shared.
Lawsuits were filed on August 15, August 27, September 5 and August 28, 2025, against Teva, Apotex and MSN over LYBALVI patents expiring between 2032 and 2041.
The AG agreement will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2025.
Alkermes plc appointed Joshua Reed as Senior Vice President and Chief Financial Officer, effective September 15, 2025, replacing an interim arrangement in which Blair C. Jackson performed the principal financial officer role. Reed brings more than 30 years of financial leadership experience, including prior CFO roles at Omega Therapeutics and Aldeyra Therapeutics, and his compensation includes a $615,000 base salary and a $3.5 million new hire equity grant.
Joshua Reed becomes CFO effective September 15, 2025, and will report to CEO Richard Pops
Initial base salary of $615,000 with a target annual cash incentive of 50% of base salary, pro-rated for 2025
New hire equity grant with an aggregate target value of $3.5 million, about 67% stock options and 33% restricted stock units
Change-in-control severance includes a lump sum of one and one-half times base salary plus average incentive pay
Alkermes reported second quarter 2025 results, with total revenues of $390.7 million, down from $399.1 million a year earlier, and GAAP net income from continuing operations of $87.1 million, down from $94.7 million. Proprietary product net sales rose to $307.2 million from $269.3 million, but the decline in manufacturing and royalty revenues drove the overall drop, and the company reiterated its 2025 financial expectations.
Total revenues were $390.7 million versus $399.1 million in the second quarter of 2024.
GAAP diluted earnings per share from continuing operations were $0.52, compared with $0.55 a year earlier.
Proprietary net sales rose to $307.2 million, with LYBALVI at $84.3 million and ARISTADA at $101.3 million.
The company reiterated 2025 total revenue expectations of $1,340 million to $1,430 million, as set forth in its February 12, 2025 release.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alkermes filing is on SEC EDGAR ↗. 8-K briefs of other companies →